-
公开(公告)号:US20170071904A1
公开(公告)日:2017-03-16
申请号:US15309176
申请日:2015-05-08
发明人: Stefan Sperl , Franz Obermayr
IPC分类号: A61K31/381 , A61K9/00
CPC分类号: A61K31/381 , A61K9/0048 , A61K31/196 , A61K31/277 , A61K31/341 , A61K31/42 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/4704 , A61K47/10 , A61K47/32 , A61K47/38
摘要: The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans or animals. More particularly, it relates to DHODH inhibitor compounds and their use for the treatment of ophthalmic diseases and disorders. The invention also relates to the local administration of such ophthalmic compositions, and in particular to their intravitreal administration. The invention relates also to controlled release formulations of therapeutically active agents, in particular of DHODH inhibitor compounds administered intraocularly, in particular in the posterior segment of the eye.
摘要翻译: 本发明一般涉及眼部治疗领域及其用于人或动物的发展。 更具体地,涉及DHODH抑制剂化合物及其用于治疗眼科疾病和病症的用途。 本发明还涉及这种眼用组合物的局部给药,特别涉及其玻璃体内给药。 本发明还涉及治疗活性剂的控制释放制剂,特别是眼内施用的DHODH抑制剂化合物,特别是在眼后段。
-
公开(公告)号:US11730716B2
公开(公告)日:2023-08-22
申请号:US15309176
申请日:2015-05-08
发明人: Stefan Sperl , Franz Obermayr
IPC分类号: A61K31/381 , A61K9/00 , A61K31/196 , A61K47/10 , A61K47/32 , A61K31/4418 , A61K31/47 , A61K31/4704 , A61K31/341 , A61K31/44 , A61K31/277 , A61K31/42 , A61K47/38
CPC分类号: A61K31/381 , A61K9/0048 , A61K31/196 , A61K31/277 , A61K31/341 , A61K31/42 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/4704 , A61K47/10 , A61K47/32 , A61K47/38
摘要: The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans or animals. More particularly, it relates to DHODH inhibitor compounds and their use for the treatment of ophthalmic diseases and disorders. The invention also relates to the local administration of such ophthalmic compositions, and in particular to their intravitreal administration. The invention relates also to controlled release formulations of therapeutically active agents, in particular of DHODH inhibitor compounds administered intraocularly, in particular in the posterior segment of the eye.
-